NEOVACS (ALNEV.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALNEV - FR0014010856 - Common Stock
ALNEV.PA Key Statistics, Chart & Performance
The current stock price of ALNEV.PA is 0.0173 EUR. In the past month the price decreased by -69.54%. In the past year, price decreased by -100%.
ALNEV.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 72.89 | 48.33B | ||
| 1AE.DE | ARGENX SE | 72.72 | 48.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.56B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.44B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.76B | ||
| 5CV.DE | CUREVAC NV | 5.09 | 996.15M | ||
| NANO.PA | NANOBIOTIX | N/A | 869.81M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 547.70M | ||
| ALCLS.PA | CELLECTIS | N/A | 453.47M | ||
| FYB.DE | FORMYCON AG | N/A | 423.20M |
Related stock screener links
About ALNEV.PA
Company Profile
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The company is headquartered in Suresnes, Ile-De-France and currently employs 20 full-time employees. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
Company Info
NEOVACS
14 Rue De La Republique
Suresnes ILE-DE-FRANCE FR
Employees: 22
Phone: 33153109300
NEOVACS / ALNEV.PA FAQ
What does ALNEV do?
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The company is headquartered in Suresnes, Ile-De-France and currently employs 20 full-time employees. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
What is the current price of ALNEV stock?
The current stock price of ALNEV.PA is 0.0173 EUR. The price decreased by -5.46% in the last trading session.
Does ALNEV stock pay dividends?
ALNEV.PA does not pay a dividend.
How is the ChartMill rating for NEOVACS?
ALNEV.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How many employees does NEOVACS have?
NEOVACS (ALNEV.PA) currently has 22 employees.
Can you provide the ownership details for ALNEV stock?
You can find the ownership structure of NEOVACS (ALNEV.PA) on the Ownership tab.
ALNEV.PA Technical Analysis
ALNEV.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALNEV.PA. ALNEV.PA may be in some trouble as it scores bad on both profitability and health.
ALNEV.PA Financial Highlights
Over the last trailing twelve months ALNEV.PA reported a non-GAAP Earnings per Share(EPS) of -33334.67. The EPS increased by 64.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -149.13% | ||
| ROE | -182.23% | ||
| Debt/Equity | 0.01 |